Protein expression patterns of cell cycle regulators in operable breast cancer

Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs

(2016) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer

(2016) Satu Luhtala et al.   TUMOR BIOLOGY

Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status

(2015) Gou Watanabe et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo

(2015) Stian Knappskog et al.   Molecular Oncology

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer

(2014) Andrew R. Green et al.   BREAST CANCER RESEARCH AND TREATMENT

Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy

(2014) Ilenia Migliaccio et al.   CURRENT OPINION IN ONCOLOGY

The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis

(2013) Xiao-Ling Xu et al.   BREAST CANCER RESEARCH AND TREATMENT

D-type Cyclins are important downstream effectors of cytokine signaling that regulate the proliferation of normal and neoplastic mammary epithelial cells

(2013) Qian Zhang et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

A Crosstalk Imbalance Between p27Kip1 and Its Interacting Molecules Enhances Breast Carcinogenesis

(2012) Weiwei He et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel

(2012) George Fountzilas et al.   PLoS One

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

(2012) Douglas G. Altman et al.   PLOS MEDICINE

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

(2011) Helen Gogas et al.   BREAST CANCER RESEARCH AND TREATMENT

A Study to investigate the role of p27 and Cyclin E immunoexpression as a prognostic factor in early breast carcinoma

(2011) Komala Pillay et al.   World Journal of Surgical Oncology

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy

(2010) Michael F. Press et al.   JOURNAL OF CLINICAL ONCOLOGY

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

(2010) Sunil Badve et al.   MODERN PATHOLOGY

Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer

(2009) R. Agarwal et al.   CLINICAL CANCER RESEARCH

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

(2009) Maggie C. U. Cheang et al.   JNCI-Journal of the National Cancer Institute

p21 and p27: roles in carcinogenesis and drug resistance

(2008) Abde M. Abukhdeir et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing

(2008) Isabelle Vanden Bempt et al.   JOURNAL OF CLINICAL ONCOLOGY

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00

(2007) G. Fountzilas et al.   ANNALS OF ONCOLOGY